Marie Bonnet, Maxime Dubosq-Lebaz, Audrey Fels, Gilles Chatellier, Yann Gouëffic
{"title":"Technical success and early outcomes of mechanical thrombectomy and thrombo-aspiration for acute limb ischemia: a systematic review and meta-analysis.","authors":"Marie Bonnet, Maxime Dubosq-Lebaz, Audrey Fels, Gilles Chatellier, Yann Gouëffic","doi":"10.23736/S0021-9509.25.13360-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, thrombo-aspiration (TA) and mechanical thrombectomy (MT) have emerged as endovascular alternatives to conventional treatments such as surgical thrombectomy or catheter-directed thrombolysis (CDT) for acute limb ischemia (ALI). To date, no meta-analysis has assessed the outcomes of TA and MT in this setting. This study aims to evaluate the short-term safety and effectiveness of these techniques in patients with ALI.</p><p><strong>Evidence acquisition: </strong>Systematic searches on studies evaluating the safety and efficacy of TA or MT in ALI were conducted in PubMed/Medline and Cochrane Central from 2010 to 2023. The meta-analysis followed PRISMA guidelines. The primary endpoint was amputation rate at 30 days. Secondary endpoints included 30-day mortality, technical success alone, and success with adjuvant treatment (angioplasty, stenting, CDT).</p><p><strong>Evidence synthesis: </strong>A total of 591 articles were screened, and 10 studies (1083 patients, 1092 limbs) were included. The pooled one-month major amputation rate was 5% [95% CI: 1-8%]. In subgroup analysis, the amputation rate was 0% [95% CI: 0-1%] for TA and 8% [95% CI: 4-13%] for MT, reflecting differences in patient severity profiles. One-month mortality was 3% [95% CI: 1-5%]. Technical success alone was 57% [95% CI: 39-75%] overall, with a marked difference between TA (73% [95% CI: 54-93%]) and MT (48% [95% CI: 16-80%]). Assisted technical success reached 97% [95% CI: 94-100%].</p><p><strong>Conclusions: </strong>Short-term outcomes of TA and MT suggest these techniques are promising for ALI treatment. However, their effectiveness relies heavily on adjunctive therapies, especially for MT. Future randomized trials and cost-effectiveness analyses with long-term follow-up are needed to define the true value of these approaches.</p>","PeriodicalId":101333,"journal":{"name":"The Journal of cardiovascular surgery","volume":"66 4","pages":"337-346"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of cardiovascular surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0021-9509.25.13360-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: In recent years, thrombo-aspiration (TA) and mechanical thrombectomy (MT) have emerged as endovascular alternatives to conventional treatments such as surgical thrombectomy or catheter-directed thrombolysis (CDT) for acute limb ischemia (ALI). To date, no meta-analysis has assessed the outcomes of TA and MT in this setting. This study aims to evaluate the short-term safety and effectiveness of these techniques in patients with ALI.
Evidence acquisition: Systematic searches on studies evaluating the safety and efficacy of TA or MT in ALI were conducted in PubMed/Medline and Cochrane Central from 2010 to 2023. The meta-analysis followed PRISMA guidelines. The primary endpoint was amputation rate at 30 days. Secondary endpoints included 30-day mortality, technical success alone, and success with adjuvant treatment (angioplasty, stenting, CDT).
Evidence synthesis: A total of 591 articles were screened, and 10 studies (1083 patients, 1092 limbs) were included. The pooled one-month major amputation rate was 5% [95% CI: 1-8%]. In subgroup analysis, the amputation rate was 0% [95% CI: 0-1%] for TA and 8% [95% CI: 4-13%] for MT, reflecting differences in patient severity profiles. One-month mortality was 3% [95% CI: 1-5%]. Technical success alone was 57% [95% CI: 39-75%] overall, with a marked difference between TA (73% [95% CI: 54-93%]) and MT (48% [95% CI: 16-80%]). Assisted technical success reached 97% [95% CI: 94-100%].
Conclusions: Short-term outcomes of TA and MT suggest these techniques are promising for ALI treatment. However, their effectiveness relies heavily on adjunctive therapies, especially for MT. Future randomized trials and cost-effectiveness analyses with long-term follow-up are needed to define the true value of these approaches.